[go: up one dir, main page]

MX2022009100A - Proteinas de fusion fc heterodimericas il15/il15r alfa para el tratamiento de cancer. - Google Patents

Proteinas de fusion fc heterodimericas il15/il15r alfa para el tratamiento de cancer.

Info

Publication number
MX2022009100A
MX2022009100A MX2022009100A MX2022009100A MX2022009100A MX 2022009100 A MX2022009100 A MX 2022009100A MX 2022009100 A MX2022009100 A MX 2022009100A MX 2022009100 A MX2022009100 A MX 2022009100A MX 2022009100 A MX2022009100 A MX 2022009100A
Authority
MX
Mexico
Prior art keywords
heterodimeric
cancer
treatment
fusion proteins
il15r alpha
Prior art date
Application number
MX2022009100A
Other languages
English (en)
Inventor
Alexander Joachim Paul Ungewickell
Vittal Shivva
Rajbharan Yadav
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2022009100A publication Critical patent/MX2022009100A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente divulgación proporciona métodos de tratamiento de cáncer mediante la administración de una proteína heterodimérica que comprende un primer monómero que comprende una fusión de proteína IL15 y dominio Fc, y un segundo monómero que comprende una fusión de proteína IL15Ra y dominio Fc.
MX2022009100A 2020-01-28 2021-01-28 Proteinas de fusion fc heterodimericas il15/il15r alfa para el tratamiento de cancer. MX2022009100A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062966976P 2020-01-28 2020-01-28
PCT/US2021/015552 WO2021155042A1 (en) 2020-01-28 2021-01-28 Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2022009100A true MX2022009100A (es) 2022-08-18

Family

ID=74672461

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022009100A MX2022009100A (es) 2020-01-28 2021-01-28 Proteinas de fusion fc heterodimericas il15/il15r alfa para el tratamiento de cancer.

Country Status (12)

Country Link
US (1) US20230149509A1 (es)
EP (1) EP4096698A1 (es)
JP (1) JP2023511439A (es)
KR (1) KR20220132598A (es)
CN (1) CN115397456A (es)
AU (1) AU2021213767A1 (es)
BR (1) BR112022014849A2 (es)
CA (1) CA3165460A1 (es)
IL (1) IL294944A (es)
MX (1) MX2022009100A (es)
TW (1) TW202136318A (es)
WO (1) WO2021155042A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA49517A (fr) 2017-06-30 2020-05-06 Xencor Inc Protéines de fusion fc hétérodimères ciblées contenant il-15/il-15ra et domaines de liaison à l'antigène
IL310398A (en) 2018-04-18 2024-03-01 Xencor Inc Proteins from heterodimeric il-15/il-15rα fc and their uses
US11618776B2 (en) 2018-12-20 2023-04-04 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
JP2024527047A (ja) * 2021-07-28 2024-07-19 ジェネンテック， インコーポレイテッド 血液がんの処置のためのｉｌ１５／ｉｌ１５ｒアルファヘテロ二量体ｆｃ融合タンパク質
EP4380596A1 (en) * 2021-08-04 2024-06-12 Genentech, Inc. Il15/il15r alpha heterodimeric fc-fusion proteins for the expansion of nk cells in the treatment of solid tumours
AU2023303515A1 (en) 2022-07-07 2025-01-16 Genentech, Inc. Combinations of il15/il15r alpha heterodimeric fc-fusion proteins and fcrh5xcd3 bispecific antibodies for the treatment of blood cancers
CA3263279A1 (en) * 2022-08-05 2024-02-22 Staidson Biopharma Inc. Masking polypeptide, new activatable drug products and their methods of use
WO2025085781A1 (en) 2023-10-19 2025-04-24 Genentech, Inc. Combinations of il15/il15r alpha heterodimeric fc-fusion proteins and her2xcd3 bispecific antibodies for the treatment of her2-positive cancers
WO2025233861A1 (en) * 2024-05-08 2025-11-13 Suzhou Forlong Biotechnology Co., Ltd. Long-acting il-15 agonist for treating tumor
WO2025252840A1 (en) 2024-06-04 2025-12-11 Technische Universitaet Muenchen, In Vertretung Des Freistaates Bayern Half-life modulation by a tag comprising at least one constant domain of an immunoglobulin light chain

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551576B1 (en) 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
ES2027518A6 (es) 1990-12-18 1992-06-01 Andromaco Lab Procedimiento para la preparacion de nuevas asociaciones no covalentes polisacarido-proteina con actividad farmacologica.
US7083572B2 (en) 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
US5874105A (en) 1996-01-31 1999-02-23 Collaborative Laboratories, Inc. Lipid vesicles formed with alkylammonium fatty acid salts
US6071535A (en) 1996-01-31 2000-06-06 Collaborative Laboratories, Inc. Lipid vesicles formed with alkylammonium fatty acid salts
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
EP0915987A2 (en) 1997-04-21 1999-05-19 Donlar Corporation POLY-($g(a)-L-ASPARTIC ACID), POLY-($g(a)-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE
US7195780B2 (en) 2002-10-21 2007-03-27 University Of Florida Nanoparticle delivery system
US7449443B2 (en) 2000-03-23 2008-11-11 California Institute Of Technology Method for stabilization of proteins using non-natural amino acids
US6586207B2 (en) 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
WO2003059288A2 (en) 2002-01-09 2003-07-24 Enzrel, Inc. Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds
JP2005517024A (ja) 2002-02-07 2005-06-09 イッサム リサーチ ディベロプメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム 生物学的障壁を横切る透過を促進し得るアミノ酸配列
AU2003248370A1 (en) 2002-02-27 2003-09-09 California Institute Of Technology Computational method for designing enzymes for incorporation of amino acid analogs into proteins
US7090868B2 (en) 2002-09-13 2006-08-15 University Of Florida Materials and methods for drug delivery and uptake
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
WO2005094785A2 (en) 2003-09-17 2005-10-13 Chiasma, Ltd. Compositions capable of facilitating penetration across a biological barrier
ES2831379T3 (es) 2003-10-09 2021-06-08 Ambrx Inc Derivados poliméricos para la modificación selectiva de proteínas
BRPI0507169A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
KR20070044805A (ko) 2004-04-15 2007-04-30 키아스마, 인코포레이티드 생물학적 장벽 투과를 촉진시킬 수 있는 조성물
WO2006062506A1 (en) 2004-12-03 2006-06-15 Enzrel, Inc. Chitosan-coated liposome drug delivery of antioxidant or anti-inflammatory compounds
EP2418278A3 (en) 2005-05-09 2012-07-04 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
KR101607288B1 (ko) 2005-07-01 2016-04-05 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US20070184076A1 (en) 2006-02-07 2007-08-09 Unger Evan C Liquid-filled nanodroplets for anti-cancer therapy
IL188647A0 (en) 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
CN104548091A (zh) 2008-02-11 2015-04-29 治疗科技公司 用于肿瘤治疗的单克隆抗体
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
KR101001360B1 (ko) 2008-06-16 2010-12-14 (주)기가레인 전자 기기의 접지에 전기적으로 연결되는 인쇄회로기판
EA023148B1 (ru) 2008-08-25 2016-04-29 Эмплиммьюн, Инк. Композиции на основе антагонистов pd-1 и их применение
US20110159023A1 (en) 2008-08-25 2011-06-30 Solomon Langermann Pd-1 antagonists and methods for treating infectious disease
EP3192811A1 (en) 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
DK2699264T3 (en) 2011-04-20 2018-06-25 Medimmune Llc ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1
AU2012288413B2 (en) 2011-07-24 2016-10-13 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
CN105101950B (zh) 2013-03-05 2019-10-11 安特里斯生物制药公司 口服递送的药物
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
DK3244878T3 (da) 2015-01-12 2022-10-17 Enteris Biopharma Inc Faste orale sammensætningsformer
CA3040504A1 (en) * 2016-10-14 2018-04-19 Xencor, Inc. Il15/il15ra heterodimeric fc-fusion proteins
IL310398A (en) * 2018-04-18 2024-03-01 Xencor Inc Proteins from heterodimeric il-15/il-15rα fc and their uses

Also Published As

Publication number Publication date
BR112022014849A2 (pt) 2022-10-11
US20230149509A1 (en) 2023-05-18
IL294944A (en) 2022-09-01
CN115397456A (zh) 2022-11-25
KR20220132598A (ko) 2022-09-30
TW202136318A (zh) 2021-10-01
JP2023511439A (ja) 2023-03-17
WO2021155042A1 (en) 2021-08-05
CA3165460A1 (en) 2021-08-05
AU2021213767A1 (en) 2022-07-28
EP4096698A1 (en) 2022-12-07

Similar Documents

Publication Publication Date Title
MX2022009100A (es) Proteinas de fusion fc heterodimericas il15/il15r alfa para el tratamiento de cancer.
PH12019502621A1 (en) Antibody-cytokine engrafted proteins and methods of use in the treatement of cancer
PH12021550802A1 (en) Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
WO2021181233A3 (en) Cd80-fc fusion protein and uses thereof
PH12022552122A1 (en) Antibodies and fusion proteins that bind to ccr8 and uses thereof
EP4431109A3 (en) Combination of multimeric fusion polypeptides and immune checkpoint inhibitor for treating hpv-associated cancer
MX2021006017A (es) Polipeptidos de folistatina y sus usos.
MX2021008207A (es) Proteínas de fusión multifuncionales y usos de las mismas.
MX2024014468A (es) Anticuerpos anti-cd63, conjugados y usos de estos
MX2021010039A (es) Novedosas proteinas de fusion especificas para cd137 y gpc3.
MY200710A (en) Novel fusion protein specific for cd137 and pd-l1
WO2022150732A3 (en) Chimeric receptor therapy
MX2024005705A (es) Composiciones de liquidos ionicos.
MX2024001211A (es) Proteinas de fusion fc heterodimericas il15/il15r alfa para el tratamiento de tipos de cancer de sangre.
MX2021002208A (es) Regimenes de dosificacion de la proteina de fusion de fc y dominio extracelular del cd80.
CO2020016105A2 (es) Proteínas inmunodominantes y fragmentos en esclerosis múltiple
EP4582446A3 (en) Methods of treating al amyloidosis
WO2022026902A3 (en) Chimeric proteins and methods of use for treatment of central nervous system disorders
WO2021151043A3 (en) Methods and compositions for treating and preventing viral infection
ZA202110285B (en) Antibodies and methods of use
WO2020172482A3 (en) Cd80 extracellular domain-fc fusion proteins for treating pd-l1 negative tumors
MX2025000124A (es) Combinaciones de proteinas de fusion a fc heterodimericas il15/il15r alfa y anticuerpos biespecificos fcrh5xcd3 para el tratamiento de tipos de cancer de sangre
MX2022003010A (es) Tratamiento de la emr mediante cambio de terapia.
MX2025008431A (es) Proteinas de fusion fc de il-12
WO2021178960A3 (en) Compositions and methods for treatment of cancer